Patents by Inventor Xin Zhai

Xin Zhai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Powder dry-pressing molding device and method
    Patent number: 11938653
    Abstract: The present invention relates to a powder dry-pressing molding device and method.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: March 26, 2024
    Assignees: QINGDAO UNIVERSITY OF TECHNOLOGY, SHENYANG HONGYANG PRECISION CERAMICS CO., LTD.
    Inventors: Changhe Li, Mingcun Shi, Xiangyang Ma, Baoda Xing, Xiaohong Ma, Yanbin Zhang, Min Yang, Xin Cui, Teng Gao, Xiaoming Wang, Yali Hou, Han Zhai, Zhen Wang, Bingheng Lu, Huajun Cao, Naiqing Zhang, Qidong Wu
  • Quinoline derivatives and their applications
    Patent number: 9783499
    Abstract: The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R1, R2, X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity against c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: October 10, 2017
    Assignee: Shenyang Pharmaceutical University
    Inventors: Ping Gong, Yanfang Zhao, Yajing Liu, Xin Zhai
  • Quinoline and cinnoline derivatives and their applications
    Patent number: 9382232
    Abstract: The present invention relates to a series of quinoline and cinnoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof. And the compounds of general formula I show potent inhibitory activity gainst c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: July 5, 2016
    Assignees: Shenyang Pharmaceutical University, Shenyang Pharmaceutical University (Benxi) Pharmaceutical Science and Technology Co., Ltd.
    Inventors: Ping Gong, Yanfang Zhao, Yajing Liu, Xin Zhai, Sai Li, Wufu Zhu, Mingze Qin
  • NOVEL QUINOLINE DERIVATIVES AND THEIR APPLICATIONS
    Publication number: 20150307453
    Abstract: The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R1, R2, X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity against c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.
    Type: Application
    Filed: May 4, 2015
    Publication date: October 29, 2015
    Inventors: Ping Gong, Yanfang Zhao, Yajing Liu, Xin Zhai
  • Quinoline and cinnoline derivatives and their applications
    Publication number: 20140364431
    Abstract: The present invention relates to a series of quinoline and cinnoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof. And the compounds of general formula I show potent inhibitory activity gainst c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.
    Type: Application
    Filed: December 7, 2012
    Publication date: December 11, 2014
    Inventors: Ping Gong, Yanfang Zhao, Yajing Liu, Xin Zhai, Sai Li, Wufu Zhu, Mingze Qin